You're reading the free version. Trader adds the live tape and alerts.
Start tracking
ACAD Sale Disclosure
Schneyer Mark C. · SEC Form 4 · Filed Aug 7, 2026
Sale
Calculated transaction value
$145K
Schneyer Mark C. EVP, Chief Financial Officer
ACAD
Transaction date
Aug 6, 2026
Public filing date
Aug 7, 2026
Filing lag
Filed 1 day later
ACAD daily price context
Close on/before transaction
$28.45
Aug 6, 2026
First close after public filing
$29.39
Aug 10, 2026
30-day return after filing
-6.16%
Through Sep 8, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 5,000 shares @ $29
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001899977-26-000008
Filing cohort
Transactions in this filing
Showing 7 of 7
Trades
7
Issuers
1
Estimated value
$946.56K
Buys / sales
0 / 3
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Acadia Pharmaceuticals Inc ACAD | Exercise | Aug 6, 2026 | $254.97K |
| Acadia Pharmaceuticals Inc ACAD | Sale | Aug 6, 2026 | $272.6K |
| Acadia Pharmaceuticals Inc ACAD Current | Sale | Aug 6, 2026 | $145K |
| Acadia Pharmaceuticals Inc ACAD | Exercise | Aug 6, 2026 | $0 |
| Acadia Pharmaceuticals Inc ACAD | Exercise | Aug 5, 2026 | $104.35K |
| Acadia Pharmaceuticals Inc ACAD | Exercise | Aug 5, 2026 | $0 |
| Acadia Pharmaceuticals Inc ACAD | Sale | Aug 5, 2026 | $169.64K |